News | September 20, 2024
Abbott India inks non-exclusive patent license agreement with Takeda for Vonoprazan
This license will enable Abbott to enhance access to this novel therapy to more patients across India
This license will enable Abbott to enhance access to this novel therapy to more patients across India
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Secretary Vaidya Rajesh Kotecha has urged senior officials to strive for the successful attainment of targets during the campaign
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Agreement further expands Aptar Pharma’s leading respiratory portfolio
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Rad-Sure blood irradiation indicators are FDA 510 (k) cleared medical devices that offer positive visual verification of irradiation at the minimum specified dose
Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
